CellPro Inc. said that Christopher Porter, vice chairman andCEO, has left the company to form Medical Genesis, an advisorygroup to assist new medical technology startups. RichardMurdock, president of CellPro will assume the additional role ofCEO. Murdock joined CellPro as vice president of marketing andcorporate development in September 1991 and was appointedpresident in December. The Bothell, Wash., company(NASDAQ:CPRO) also named S. Joseph Tarnowski vice presidentof operations. He was previously director of process andproduct development for Scios Inc. CellPro specializes in thedevelopment and manufacture of cell selection systems for usein therapeutic, diagnostic and research applications.
Ralph Christofferson was named president and CEO of RibozymePharmaceuticals Inc. He was a senior vice president atSmithKline Beecham. Privately held Ribozyme Pharmaceuticalsof Cleveland is focused on commercializing the ribozymetechnology developed by Thomas R. Cech.
Joshua Boger was named CEO at Vertex Pharmaceuticals Inc. Hewill continue as president and chief scientific officer. Vertex(NASDAQ:VRTX) of Cambridge, Mass., develops drugs to treathuman diseases.
SciClone Pharmaceuticals Inc. named Marc Steuer chieffinancial officer and vice president of licensing andacquisitions. Steuer was formerly vice president and generalmanager of ventures and licensing for Pilkington Visioncare.SciClone (NASDAQ:SCLN) of San Mateo, Calif., is focused ontherapeutics for life-threatening or chronic infectious diseases,cancers and immune system disorders.
Bio-Technology General Corp. appointed Nadim Kassem to thenewly created position of senior vice president/chief medicalofficer and Kevin Reddington to senior vice president-finance/chief financial officer. Kassem worked at Schering Corp.in a variety of senior clinical research positions. Reddingtonwas vice president of mergers and acquisitions at BoehringerIngelheim Corp. BTGC (NASDAQ:BTGC) of New York is engagedin the research, development and manufacture of products forhuman and animal health care.
Menlo Park, Calif.-based Liposome Technology Inc. namedJoseph M. Limber vice president for marketing and sales.Limber was director of marketing for Syntex Corp. LTIZ alsonamed Michael W. Ramsay associate director of manufacturing.He was manager of corporate technology assessment at Syntex .The company (NASDAQ:LTIZ) is developing liposome and lipid-based products to treat life-threatening illnesses.
(c) 1997 American Health Consultants. All rights reserved.